NCT04321174 (CORIPREV-LR) is a Phase 3 clinical trial of Lopinavir/ritonavir in Coronavirus Infections, sponsored by Unity Health Toronto.

Who is sponsoring NCT04321174?

NCT04321174 is sponsored by Unity Health Toronto.

What drugs are being tested in NCT04321174?

Interventions in NCT04321174: Lopinavir/ritonavir.

What condition does NCT04321174 study?

NCT04321174 studies Coronavirus Infections, Post-exposure Prophylaxis.

Is NCT04321174 still recruiting?

NCT04321174 is currently status unknown. Last updated 14 December 2021.

Last reviewed 2021-12-14 · How we verify

NCT04321174: CORIPREV-LR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir

Status unknown Phase 3 Last updated 14 December 2021

What this trial tests

Phase 3 trial testing Lopinavir/ritonavir in Coronavirus Infections in 123 participants. Status unknown.

Timeline

17 April 2020

Primary endpoint
27 August 2021

31 March 2022

Quick facts

Lead sponsor	Unity Health Toronto
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	123
Start date	17 April 2020
Primary completion	27 August 2021
Estimated completion	31 March 2022
Sites	4 locations across Canada

Drugs / interventions tested

Lopinavir/ritonavir

Conditions studied

Coronavirus Infections — all drugs for Coronavirus Infections →
Post-exposure Prophylaxis — all drugs for Post-exposure Prophylaxis →

Sponsor

Unity Health Toronto — full company profile →

Who can join

18 Months and older, any sex, with Coronavirus Infections or Post-exposure Prophylaxis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COVID-19 has rapidly evolved into a generalized global pandemic. Post-exposure prophylaxis (PEP) against on COVID-19 was identified as an urgent research priority by the WHO, and lopinavir/ritonavir (LPV/r) is a promising candidate for both COVID-19 treatment and PEP, with a good safety profile and global availability. This is a cluster randomized controlled trial (RCT) of oral LPV/r as PEP against COVID-19, that will address the immediate need for preventive interventions, generate key data on COVID-19 transmission, and serve as a research platform for future vaccines and preventive agents.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lopinavir/ritonavir

Trials testing the same drug.

NCT04364022 — Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland · Phase 3 · completed
NCT04394182 — Ultra Low Doses of Therapy With Radiation Applicated to COVID-19 · NA · suspended
NCT04315948 — Trial of Treatments for COVID-19 in Hospitalized Adults · Phase 3 · completed
NCT04307693 — Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) · Phase 2 · terminated
NCT04276688 — Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment · Phase 2 · completed

Other recruiting trials for Coronavirus Infections

Currently open trials in the same condition.

NCT06631287 — Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Sym · Phase 3 · recruiting
NCT05276388 — Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-CoV-2 Infection (COVID-19) · active not recruiting
NCT04429594 — Study of the Incidence of SARS-CoV-2 Infection (COVID-19) · NA · recruiting
NCT04327570 — In-depth Immunological Investigation of COVID-19. · recruiting
NCT04318366 — COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor · recruiting

Other Unity Health Toronto trials

Trials by the same sponsor.

NCT07507409 — Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients · Phase 4 · not yet recruiting
NCT07455487 — First Appendectomy Using Revolve Surgical Robotic Arm · NA · not yet recruiting
NCT07301632 — Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial · Phase 2 · recruiting
NCT07314905 — Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) · Phase 3 · not yet recruiting
NCT06571916 — Brief Skills for Safer Living (Brief-SfSL) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04321174 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Unity Health Toronto
Last refreshed: 14 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04321174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing